Nagase et al. summarizes the consensus definition of clinical remission adopted in the 2024 Japanese Asthma Prevention and Management Guidelines (JGL 2024).2 Through a two-round modified Delphi process, experts agreed on four core components: absence of exacerbations, well-controlled symptoms, no continuous oral corticosteroid use, and optimization of lung function—defined as normal when achievable and stable when fixed airflow limitation is present.

Hamada et al. focuses on severe asthma, where biologics targeting IL-5, IL-4/13, thymic stromal lymphopoietin, and IgE have transformed disease control.3 Across trials and real-world studies, approximately one-third of patients achieve clinical remission, although prevalence varies with definitions and baseline characteristics.

Tamaki revisits remission in EGPA, traditionally defined by BVAS-based inactivity of vasculitis.4 Emerging evidence highlights the inadequacy of classifying patients as "in remission" while they remain dependent on glucocorticoids, even at low doses. Recent biologic trials now include stringent steroid thresholds (e.g., prednisone ≤4 mg/day) within primary endpoints, reflecting a shift toward minimizing glucocorticoid toxicity as a core dimension of remission.